MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$102,403K
Free Cash flow
$57,154K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Accounts receivable, net
Prepaid expenses
Others
Negative Cash Flow Breakdown
Purchases of property and equipm...
Gain on exchange of long-term in...
Purchases of marketable securiti...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-18,551
-6,967
-8,373
-12,585
Depreciation
760
197
202
253
Amortization of intangible assets
240
240
241
240
Amortization of debt-related costs
166
159
156
152
Loss on disposal of property and equipment
-183
-
-
-
Stock-based compensation
13,289
11,967
14,314
12,243
Loss on debt extinguishment
-
-
0
0
Non-cash lease expense
92
77
154
205
Gain on exchange of long-term investments
2,812
-
-
-
Net amortization/accretion of marketable securities
762
849
925
1,534
Realized loss on equity investments
-
-
-
0
Realized/unrealized loss (gain) on equity investments
-
-
0
-
Change in fair value of equity warrants issued by licensee
-
-
0
0
Unrealized (gain) loss from transactions denominated in a foreign currency
24
-
-
12
Accounts receivable, net
-19,315
30,287
12,437
14,286
Inventory
-198
196
536
-37
Other receivables
396
-189
336
-190
Prepaid expenses
-17,105
13,244
-8,187
-7,978
Other non-current assets
-55
-141
381
373
Accounts payable
15,696
7,714
-30,539
23,842
Accrued payroll and benefits
3,358
-9,250
4,228
1,940
Other accrued liabilities
13,297
15,457
45,389
-
Other long-term liabilities
-
-
0
0
Net cash provided by (used in) operating activities
61,223
-24,652
19,330
18,257
Proceeds from maturities of marketable securities
44,349
74,055
92,082
99,500
Purchases of marketable securities
2,402
126,799
35,580
102,333
Purchases of long-term investments
-
-
870
0
Intangible asset additions
-
-
0
-
Purchases of property and equipment
4,069
5,818
6,358
1,910
Net cash used in investing activities
37,878
-58,562
49,274
-4,743
Proceeds from issuance of common stock, net of paid issuance costs
0
-134,771
-
0
Proceeds from issuance of common stock, net of paid issuance costs-Common Stock
-
-
134,771
-
Proceeds from issuance of pre-funded warrants, net of paid issuance costs
-
-
0
0
Proceeds from sale of common stock under employee stock purchase plan
1,438
-
1,236
0
Proceeds from exercise of stock options
1,864
1,204
1,076
2,562
Proceeds from issuance of common stock, net of paid issuance costs-A2023ATMProspectus
-
-
0
-
Proceeds from long-term debt
-
-
0
0
Payment of debt issuance costs
-
-
0
0
Payments for debt extinguishment
-
-
0
0
Net cash provided by financing activities
3,302
1,204
2,312
2,562
Net increase in cash, cash equivalents and restricted cash
102,403
-82,010
70,916
16,076
Cash, cash equivalents and restricted cash at beginning of period
104,193
186,203
115,287
97,381
Cash, cash equivalents and restricted cash at end of period
206,596
104,193
186,203
115,287
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Accounts receivable, net
-$19,315K
(-266.88%↓ Y/Y)
Prepaid expenses
-$17,105K
(-218.38%↓ Y/Y)
Accounts payable
$15,696K
(15.39%↑ Y/Y)
Other accrued
liabilities
$13,297K
Proceeds from maturities
of marketable...
$44,349K
(-73.95%↓ Y/Y)
Proceeds from exercise of
stock options
$1,864K
(-29.45%↓ Y/Y)
Proceeds from sale of
common stock under...
$1,438K
(30.61%↑ Y/Y)
Stock-based compensation
$13,289K
(-12.36%↓ Y/Y)
Accrued payroll and
benefits
$3,358K
(179.72%↑ Y/Y)
Depreciation
$760K
(90.00%↑ Y/Y)
Amortization of intangible
assets
$240K
(-50.00%↓ Y/Y)
Inventory
-$198K
(-115.81%↓ Y/Y)
Loss on disposal of
property and equipment
-$183K
Amortization of debt-related
costs
$166K
(-41.75%↓ Y/Y)
Non-cash lease expense
$92K
(-71.52%↓ Y/Y)
Other non-current
assets
-$55K
(75.77%↑ Y/Y)
Net cash provided by
(used in) operating...
$61,223K
(222.35%↑ Y/Y)
Net cash used in
investing activities
$37,878K
(143.72%↑ Y/Y)
Net cash provided by
financing activities
$3,302K
(-97.62%↓ Y/Y)
Canceled cashflow
$22,545K
Canceled cashflow
$6,471K
Net increase in
cash, cash...
$102,403K
(5495.79%↑ Y/Y)
Net loss
-$18,551K
(59.19%↑ Y/Y)
Gain on exchange of
long-term investments
$2,812K
Net
amortization/accretion of marketable...
$762K
(-74.79%↓ Y/Y)
Other receivables
$396K
(-34.87%↓ Y/Y)
Unrealized (gain) loss from
transactions denominated in a...
$24K
(192.31%↑ Y/Y)
Purchases of property and
equipment
$4,069K
(155.75%↑ Y/Y)
Purchases of marketable
securities
$2,402K
(-99.06%↓ Y/Y)
Buy us a coffee
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS)